Dual-Function Antibody PD-1/CTLA-4

DRUG2 trials

Sponsors

Ruijin Hospital

Conditions

Pancreatic Adenocarcinoma Locally Advanced

Phase 2

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

RecruitingNCT07306273

Ruijin HospitalPancreatic Adenocarcinoma Locally Advanced

Start: 2025-12-15End: 2027-08-01Target: 20Updated: 2025-12-29

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

RecruitingNCT07306286

Ruijin HospitalPancreatic Adenocarcinoma Locally Advanced

Start: 2025-12-15End: 2027-08-01Target: 20Updated: 2025-12-29